Table 3 Characteristics of patients
From: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
Age Mean ± SD (range) | 60 ± 17 y (22–81) |
Leukocyte (109/L) | 46 ± 44 (3.2–184) |
FAB subtypes | |
1 | 23% (7/31) |
2 | 23% (7/31) |
4 | 16% (5/31) |
5 | 13% (4/31) |
Myelodysplastic syndrome | 26% (8/31) |
Karyotype | |
Favorable | 6% (2/31) |
Intermediate | 71% (22/31) |
Poor | 19% (6/31) |
Not done | 3% (1/31) |
CD34 | |
Positive | 55% (17/31) |
Negative | 42% (13/31) |
Not done | 3% (1/31) |
P-gp activity | |
Mean D ± SD (range) | 0.1 ± 0.1 (0–0.7) |
Positive D > 0.3 | 23% (7/31) |
Negative D < 0.3 | 77% (24/31) |